Adenocarcinoma of the Extrahepatic Bile Duct Completed Phase 2 Trials for Trastuzumab (DB00072)

IndicationStatusPhase
DBCOND0030457 (Adenocarcinoma of the Extrahepatic Bile Duct)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00478140Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by SurgeryTreatment